Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pancreatic Neoplasms 17Carcinoma, Non-Small-Cell Lung 9Triple Negative Breast Neoplasms 8Lung Neoplasms 7Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neoplasm Metastasis 4Biliary Tract Neoplasms 4Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Esophageal Squamous Cell Carcinoma 3Cholangiocarcinoma 3Stomach Neoplasms 2Pancreatic Adenocarcinoma 2Ovarian Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Neoplasms, Basal Cell 1Muscle-Invasive Bladder Carcinoma 1Metastatic Pancreatic Ductal Adenocarcinoma 1Metastatic Pancreatic Adenocarcinoma 1Melanoma, Cutaneous Malignant 1Lymphoma 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced Pancreatic Cancer 1

Interventions

apatinib 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Triple Negative Breast Cancer × Albumin-Bound Paclitaxel × Clear all
NCT05019690 2024-09-19

Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Fujian Cancer Hospital

Phase 1/2 Recruiting
29 enrolled
Breast

Advanced Triple Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡